How do I buy Cytokinetics Inc (CYTK) stock?

Buying Cytokinetics Inc (CYTK) stock is now easy and instant through the Gotrade app. Download the Gotrade app from the App Store or Google Play. Create an account and verify your identity. Make a deposit. Search for the code "CYTK", then tap "Trade". Tap the "Buy" button. Enter the amount you want to buy. You have two options: Buy CYTK by number of shares. Buy fractional shares in dollars, starting from $1. Swipe up to confirm your order, and you're done!

What is the minimum investment for CYTK on Gotrade?

On Gotrade , you don't have to buy a full share. With fractional shares, you can start investing in Cytokinetics Inc from just $1. A small budget shouldn't stop you from building a US stock portfolio.

Does Cytokinetics Inc (CYTK) pay dividends?

At the moment, Cytokinetics Inc (CYTK) does not pay dividends because it focuses on reinvesting profits for company growth (a growth stock). However, you can still potentially earn profit from share price increases (capital gains). Track CYTK's performance via the price chart in the Gotrade app.

Is buying CYTK on Gotrade safe and legal?

Gotrade is the trading name of Gotrade Securities Inc., which is registered with and supervised by the Labuan Financial Services Authority (LFSA).

What are the market hours to buy CYTK?

You can place an order any time. It goes through when the US market (NYSE/NASDAQ) opens: 9:30 AM to 4:00 PM New York time, Monday to Friday. Pre-market and after-hours trading are open too. The market is closed on US public holidays. The Gotrade app shows whether the market is open.

How do I tell if CYTK is expensive or cheap?

There's no single perfect answer, but common approaches include: Compare valuation (e.g., P/E, P/S) against historical averages or competitors. Review revenue and earnings growth. Check margins and cash flow. Evaluate business outlook and the company's position within its industry. You can combine fundamental analysis with an investing strategy that matches your risk profile. All of the information above can be viewed directly in the Gotrade app.

Cytokinetics Inc (CYTK) Stock Price: Nov 11 Close $58.53

Latest news

Zacks Investment Research

Stocktwits Pharma Pulse: JNJ Earnings, Cancer Updates And Two FDA Target Dates — The Week’s Biotech Watchlist

CYTKOctober 12, 2026

Stocktwits

Stocktwits Pharma Pulse: JNJ Earnings, Cancer Updates And Two FDA Target Dates — The Week’s Biotech Watchlist

CYTK

MarketBeat

Cytokinetics Maps MYQORZO Expansion, Heart Failure Pipeline at Bernstein Conference

PositiveCYTKSeptember 25, 2026

MarketBeatPositive

Cytokinetics Maps MYQORZO Expansion, Heart Failure Pipeline at Bernstein Conference

CYTK

Zacks Investment Research

Can CYTK's Aficamten Strengthen Its HCM Growth Prospects?

CYTKSeptember 2, 2026

Zacks Investment Research

Can CYTK's Aficamten Strengthen Its HCM Growth Prospects?

CYTK

MarketBeat

Cytokinetics' Aficamten Hits Dual Phase III Endpoints in Non-Obstructive HCM

CYTKAugust 28, 2026

MarketBeat

Cytokinetics' Aficamten Hits Dual Phase III Endpoints in Non-Obstructive HCM

CYTK

Reuters

Cytokinetics eyes expanded use of heart drug after promising late-stage data

CYTKAugust 28, 2026

Reuters

Cytokinetics eyes expanded use of heart drug after promising late-stage data

CYTK

Investors Business Daily

Cytokinetics Scores A First-Ever In Its Rivalry Against Bristol Myers

CYTKAugust 28, 2026

Investors Business Daily

Cytokinetics Scores A First-Ever In Its Rivalry Against Bristol Myers

CYTK

The Motley Fool

Insider Transaction: Cytokinetics CEO Robert Blum Sells 7,500 Shares for $575,700

CYTKAugust 22, 2026

The Motley Fool

Insider Transaction: Cytokinetics CEO Robert Blum Sells 7,500 Shares for $575,700

CYTK

Zacks Investment Research

Cytokinetics Gains 20.5% YTD: Buy, Sell or Hold the Stock?

CYTKAugust 19, 2026

Zacks Investment Research

Cytokinetics Gains 20.5% YTD: Buy, Sell or Hold the Stock?

CYTK

News tone: automated (AI) classification of the article's content, not a price prediction.

About Cytokinetics Inc

Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

SectorHealthcare

IndustryBiotechnology

Employees673

CEOMr. Robert I. Blum

IPO DateApr 29, 2004

HeadquartersSouth San Francisco, CA

Key Executives

Name	Title	Year Born
Mr. Robert I. Blum	CEO, President & Director	1964
Dr. James H. Sabry M.D., Ph.D.	Co-Founder & Chairman of Scientific Advisory Board	1958
Mr. Sung H. Lee	EVP & CFO	1970
Mr. Jeffrey J. Hessekiel J.D.	Executive VP, Chief Legal & Administrative Officer	1969
Dr. Fady Ibraham Malik FACC, M.D., Ph.D.	Executive Vice President of Research & Development	1964
Mr. Andrew M. Callos	Executive VP & Chief Commercial Officer	1969
Dr. James A. Spudich Ph.D.	Co-Founder & Member of Scientific Advisory Board	1942
Ms. Holly Laughlin	VP of Accounting & Corporate Controller	—
Mr. Steven M. Cook J.D.	Senior Vice President of Global Supply Chain Operations & Technical Operations	1959
Mr. Scott R. Jordan	Senior Vice President of Global Marketing & Commercial Strategy	—

Fundamentals

Valuation

Price-to-sales ratio69.08

Price-to-book value-24.37

PEG ratio-0.42

Profitability

Return on Equity157.00%

Return on Assets-48.00%

Return on Sales-635.00%

Gross margin (latest quarter)95.34%

EBITDA$-706.09M

Trading

Average volume1,914,916

Source: third-party data provider, as of November 13, 2026

Technical indicators

RSI 14: 42.87
MACD 12/26/9: -2.25
EMA 9 of MACD: -1.95
MACD histogram: -0.30
SMA 50: $64.78; Price below SMA 50
EMA 50: $64.36; Price below EMA 50
SMA 200: $69.87; Price below SMA 200
EMA 200: $67.48; Price below EMA 200

Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.

Analyst views

5 analyst ratings

Third-party analyst opinion, not a recommendation from Gotrade.

Analyst consensus:Buy

100% Buy

0% Hold

0% Sell

Analyst price target

Low: $100.00
Average: $113.60
High: $140.00

Citigroup

Eric Joseph

Buy

Target price

$105.00

HC Wainwright & Co.

Joseph Pantginis

Buy

Target price

$140.00

RBC Capital

Leonid Timashev

Buy

Target price

$113.00

William Blair

Alethia Young

Buy

Target price

-

Leerink Partners

Roanna Ruiz

Buy

Target price

$100.00

Seasonality

Monthly price change (%)

	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec
2021											+0.4	+23.5
2022	-27.8	+5.2	+2.4	+3.9	-0.1	-2.9	+3.2	+28.8	-9.8	-14.6	-1.1	+12.1
2023	-4.2	+1.2	-18.4	-0.8	-0.2	-14.1	-0.0	+7.5	-18.2	+25.0	-4.6	+148.7
2024	-7.1	-11.1	-5.2	-16.0	-23.4	+8.6	+7.9	-1.4	-3.2	-3.0	+0.1	-7.1
2025	+1.1	-5.1	-6.3	+14.2	-27.7	+5.9	+11.9	-3.7	+10.8	+13.9	+13.5	-3.8
2026	+2.4	-4.5	+7.3	-4.0	+21.2	+15.6	-9.5	-7.2	-7.7	-4.0	-5.6

Compare stocks

CYTK

Buy CYTK

Market cap

$8.15B

-

Price / Earnings ratio

-10.10

-

Price / Sales ratio

69.08

-

Dividend yield

0.00%

-

Average volume

1,914,916

-

Earnings per share

$-6.04

-

Cytokinetics Inc (CYTK) Stock

Key stats

Compare with CYTK

Recent news

Cytokinetics (CYTK) Expected to Beat Earnings Estimates: Should You Buy?

Cytokinetics (CYTK) Expected to Beat Earnings Estimates: Should You Buy?

Can Myqorzo's Expansion and Growing Adoption Drive CYTK's Growth?

Can Myqorzo's Expansion and Growing Adoption Drive CYTK's Growth?

Stocktwits Pharma Pulse: JNJ Earnings, Cancer Updates And Two FDA Target Dates — The Week’s Biotech Watchlist

Stocktwits Pharma Pulse: JNJ Earnings, Cancer Updates And Two FDA Target Dates — The Week’s Biotech Watchlist

Cytokinetics Maps MYQORZO Expansion, Heart Failure Pipeline at Bernstein Conference

Cytokinetics Maps MYQORZO Expansion, Heart Failure Pipeline at Bernstein Conference

Technical indicators

Analyst ratings

Financials

Performance

Debt & Balance Sheet

Revenue to Profit

Earnings

Latest news

Cytokinetics (CYTK) Expected to Beat Earnings Estimates: Should You Buy?

Cytokinetics (CYTK) Expected to Beat Earnings Estimates: Should You Buy?

Can Myqorzo's Expansion and Growing Adoption Drive CYTK's Growth?

Can Myqorzo's Expansion and Growing Adoption Drive CYTK's Growth?

Stocktwits Pharma Pulse: JNJ Earnings, Cancer Updates And Two FDA Target Dates — The Week’s Biotech Watchlist

Stocktwits Pharma Pulse: JNJ Earnings, Cancer Updates And Two FDA Target Dates — The Week’s Biotech Watchlist

Cytokinetics Maps MYQORZO Expansion, Heart Failure Pipeline at Bernstein Conference

Cytokinetics Maps MYQORZO Expansion, Heart Failure Pipeline at Bernstein Conference

Can CYTK's Aficamten Strengthen Its HCM Growth Prospects?

Can CYTK's Aficamten Strengthen Its HCM Growth Prospects?

Cytokinetics' Aficamten Hits Dual Phase III Endpoints in Non-Obstructive HCM

Cytokinetics' Aficamten Hits Dual Phase III Endpoints in Non-Obstructive HCM

Cytokinetics eyes expanded use of heart drug after promising late-stage data

Cytokinetics eyes expanded use of heart drug after promising late-stage data

Cytokinetics Scores A First-Ever In Its Rivalry Against Bristol Myers

Cytokinetics Scores A First-Ever In Its Rivalry Against Bristol Myers

Insider Transaction: Cytokinetics CEO Robert Blum Sells 7,500 Shares for $575,700

Insider Transaction: Cytokinetics CEO Robert Blum Sells 7,500 Shares for $575,700

Cytokinetics Gains 20.5% YTD: Buy, Sell or Hold the Stock?

Cytokinetics Gains 20.5% YTD: Buy, Sell or Hold the Stock?

About Cytokinetics Inc

Key Executives

Fundamentals

Valuation

Profitability

Trading

Technical indicators

Analyst views

Seasonality

Compare stocks

Market cap

Price / Earnings ratio

Price / Sales ratio

Dividend yield

Average volume

Earnings per share

Stocks in the same sector

FAQ

Trade Faster. Easier. Smarter.

#ReadyGoTrade